IDEXX Laboratories, Inc. (IDXX) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1155839,
    "name": "IDEXX Laboratories, Inc.",
    "stock_name": "IDEXX Laboratories, Inc.",
    "full_name": "IDEXX Laboratories, Inc.",
    "name_url": "stocks-analysis/idexx-laboratories-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "717.47",
    "chg": -15.26,
    "chgp": "-2.08%",
    "dir": -1,
    "prev_price": "732.73",
    "mcapval": "66,543.42",
    "mcap": "Large Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US45168D1046",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "461.9 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/idexx-laboratories-inc-1155839-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "IDEXX Laboratories Hits Day High with 14.84% Surge in Stock Price",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/idexx-laboratories-hits-day-high-with-1484-surge-in-stock-price-3671564",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/IDEXXLaboratori_priceRelatedfactors_3671564.png",
        "date": "2025-11-04 18:24:06",
        "description": "IDEXX Laboratories, Inc. has shown notable market activity, achieving an intraday high and demonstrating strong weekly and year-to-date performance. The company exhibits high management efficiency with a significant return on capital employed and a low debt-to-EBITDA ratio, attracting substantial interest from institutional investors."
      },
      {
        "title": "IDEXX Laboratories Hits New 52-Week High of $734.64, Up 42.24%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/idexx-laboratories-hits-new-52-week-high-of-73464-up-4224-3671458",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/IDEXXLaboratori_priceRelatedfactors_3671458.png",
        "date": "2025-11-04 17:45:12",
        "description": "IDEXX Laboratories, Inc. has achieved a new 52-week high, reflecting its strong performance with a one-year growth rate significantly exceeding that of the S&P 500. The company, with a market cap of USD 66,543 million, showcases solid financial metrics, including a high return on equity and manageable debt levels."
      },
      {
        "title": "Is IDEXX Laboratories, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-idexx-laboratories-inc-overvalued-or-undervalued-3637567",
        "imagepath": "",
        "date": "2025-10-21 12:04:51",
        "description": "As of 17 October 2025, the valuation grade for IDEXX Laboratories, Inc. moved from expensive to fair. The company appears fairly valued based on its current metrics. Key ratios include a P/E ratio of 60, an EV to EBITDA of 42.53, and a PEG ratio of 11.32, which suggest that while the company is not undervalued, it is also not excessively priced compared to its peers.\n\nIn comparison to its industry peers, IDEXX Laboratories has a higher P/E ratio than Abbott Laboratories at 18.36 and Thermo Fisher Scientific at 30.06, indicating a premium valuation. However, it is more competitively positioned than Intuitive Surgical, which has a P/E of 63.32. Notably, IDEXX has demonstrated strong returns, with a year-to-date return of 53.69% compared to the S&P 500's 13.30%, reinforcing its relative strength in the market...."
      },
      {
        "title": "IDEXX Laboratories, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/idexx-laboratories-valuation-grade-adjusts-from-expensive-to-fair-amid-price-decline-3640716",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/IDEXXLaboratori_valuationdot_3640716.png",
        "date": "2025-10-20 16:16:12",
        "description": "IDEXX Laboratories, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 60 and a robust Return on Capital Employed of 51.10%. Compared to peers like Abbott Laboratories and Thermo Fisher Scientific, IDEXX's stock has demonstrated strong year-to-date performance, significantly exceeding the S&P 500."
      },
      {
        "title": "Is IDEXX Laboratories, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-idexx-laboratories-inc-overvalued-or-undervalued-3634433",
        "imagepath": "",
        "date": "2025-10-20 12:22:18",
        "description": "As of 17 October 2025, the valuation grade for IDEXX Laboratories, Inc. has moved from expensive to fair. The company appears fairly valued based on its current metrics. Key ratios include a P/E ratio of 60, an EV to EBITDA of 42.53, and a PEG ratio of 11.32, which suggest a premium valuation compared to its peers. For instance, Abbott Laboratories has a P/E of 18.36, and Thermo Fisher Scientific, Inc. has an EV to EBITDA of 21.65, indicating that IDEXX is trading at a higher valuation relative to these competitors.\n\nIn terms of performance, IDEXX has outperformed the S&P 500 with a year-to-date return of 53.69% compared to the index's 13.30%. This strong performance, coupled with the fair valuation grade, suggests that while IDEXX is not undervalued, it is positioned well within its industry...."
      },
      {
        "title": "Is IDEXX Laboratories, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-idexx-laboratories-inc-overvalued-or-undervalued-3631974",
        "imagepath": "",
        "date": "2025-10-19 11:59:56",
        "description": "As of 17 October 2025, the valuation grade for IDEXX Laboratories, Inc. moved from expensive to fair, indicating a more favorable assessment of its market position. Based on the current metrics, the company appears fairly valued. Key ratios include a P/E ratio of 60, an EV to EBITDA of 42.53, and a PEG ratio of 11.32, which suggest that while the company is priced at a premium, it may be justified given its strong performance metrics.\n\nIn comparison to its peers, IDEXX Laboratories has a higher P/E ratio than Abbott Laboratories at 18.36 and Thermo Fisher Scientific at 30.06, but is lower than Intuitive Surgical at 63.32, indicating a competitive valuation landscape. Notably, IDEXX's ROE stands at an impressive 61.71%, showcasing its efficient use of equity. Over the past year, IDEXX has returned 38.13%, significantly outperforming the S&P 500's 14.08%, reinforcing the notion that the stock is positioned we..."
      },
      {
        "title": "IDEXX Laboratories, Inc. Experiences Evaluation Adjustment Amidst Mixed Market Indicators",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/idexx-laboratories-technical-trend-changes-from-bullish-to-mildly-bullish-amid-stock-price-decline-3601046",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/IDEXXLaboratori_technicaldot_3601046.png",
        "date": "2025-10-07 19:51:23",
        "description": "IDEXX Laboratories, Inc. has recently adjusted its market evaluation, with its stock priced at $627.78. The company has shown strong performance over the past year, achieving a 31.43% return, significantly outperforming the S&P 500. Technical indicators present a mixed outlook, reflecting varying trends across different time frames."
      },
      {
        "title": "Is IDEXX Laboratories, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-idexx-laboratories-inc-technically-bullish-or-bearish-3598942",
        "imagepath": "",
        "date": "2025-10-07 12:13:59",
        "description": "As of 3 October 2025, the technical trend for IDEXX Laboratories, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the monthly MACD and KST indicators, which are both bullish, while the daily moving averages also indicate a mildly bullish trend. However, the weekly MACD and RSI are bearish, suggesting some short-term weakness. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, supporting the overall mildly bullish outlook. \n\nIn terms of multi-period returns, IDEXX has outperformed the S&P 500 year-to-date and over the past year, with returns of 51.84% and 31.43% respectively, compared to the S&P 500's 14.18% and 17.82%. However, over longer periods, such as 3 years and 5 years, IDEXX has lagged behind the S&P 500...."
      },
      {
        "title": "Is IDEXX Laboratories, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-idexx-laboratories-inc-technically-bullish-or-bearish-3593666",
        "imagepath": "",
        "date": "2025-10-06 12:04:18",
        "description": "As of 3 October 2025, the technical trend for IDEXX Laboratories, Inc. has changed from bullish to mildly bullish. The weekly MACD and KST indicators are bullish, while the weekly RSI is bearish, indicating mixed signals. The daily moving averages are mildly bullish, and Bollinger Bands show a mildly bullish stance on both weekly and monthly time frames. However, Dow Theory presents a mildly bearish view on the weekly chart but is mildly bullish on the monthly. \n\nIn terms of performance, IDEXX has outperformed the S&P 500 year-to-date with a return of 52.67% compared to the S&P 500's 14.18%, and over the past year, it has also outperformed with a return of 30.54% versus 17.82%. Overall, the current technical stance is mildly bullish, driven by the bullish MACD and KST, despite some bearish signals from the RSI and Dow Theory...."
      }
    ],
    "total": 21,
    "sid": "1155839",
    "stock_news_url": "https://www.marketsmojo.com/news/idexx-laboratories-inc-1155839"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

IDEXX Laboratories Hits Day High with 14.84% Surge in Stock Price

2025-11-04 18:24:06

IDEXX Laboratories, Inc. has shown notable market activity, achieving an intraday high and demonstrating strong weekly and year-to-date performance. The company exhibits high management efficiency with a significant return on capital employed and a low debt-to-EBITDA ratio, attracting substantial interest from institutional investors.

IDEXX Laboratories Hits New 52-Week High of $734.64, Up 42.24%

2025-11-04 17:45:12

IDEXX Laboratories, Inc. has achieved a new 52-week high, reflecting its strong performance with a one-year growth rate significantly exceeding that of the S&P 500. The company, with a market cap of USD 66,543 million, showcases solid financial metrics, including a high return on equity and manageable debt levels.

Is IDEXX Laboratories, Inc. overvalued or undervalued?

2025-10-21 12:04:51

As of 17 October 2025, the valuation grade for IDEXX Laboratories, Inc. moved from expensive to fair. The company appears fairly valued based on its current metrics. Key ratios include a P/E ratio of 60, an EV to EBITDA of 42.53, and a PEG ratio of 11.32, which suggest that while the company is not undervalued, it is also not excessively priced compared to its peers. In comparison to its industry peers, IDEXX Laboratories has a higher P/E ratio than Abbott Laboratories at 18.36 and Thermo Fisher Scientific at 30.06, indicating a premium valuation. However, it is more competitively positioned than Intuitive Surgical, which has a P/E of 63.32. Notably, IDEXX has demonstrated strong returns, with a year-to-date return of 53.69% compared to the S&P 500's 13.30%, reinforcing its relative strength in the market....

IDEXX Laboratories, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics

2025-10-20 16:16:12

IDEXX Laboratories, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 60 and a robust Return on Capital Employed of 51.10%. Compared to peers like Abbott Laboratories and Thermo Fisher Scientific, IDEXX's stock has demonstrated strong year-to-date performance, significantly exceeding the S&P 500.

Is IDEXX Laboratories, Inc. overvalued or undervalued?

2025-10-20 12:22:18

As of 17 October 2025, the valuation grade for IDEXX Laboratories, Inc. has moved from expensive to fair. The company appears fairly valued based on its current metrics. Key ratios include a P/E ratio of 60, an EV to EBITDA of 42.53, and a PEG ratio of 11.32, which suggest a premium valuation compared to its peers. For instance, Abbott Laboratories has a P/E of 18.36, and Thermo Fisher Scientific, Inc. has an EV to EBITDA of 21.65, indicating that IDEXX is trading at a higher valuation relative to these competitors. In terms of performance, IDEXX has outperformed the S&P 500 with a year-to-date return of 53.69% compared to the index's 13.30%. This strong performance, coupled with the fair valuation grade, suggests that while IDEXX is not undervalued, it is positioned well within its industry....

Is IDEXX Laboratories, Inc. overvalued or undervalued?

2025-10-19 11:59:56

As of 17 October 2025, the valuation grade for IDEXX Laboratories, Inc. moved from expensive to fair, indicating a more favorable assessment of its market position. Based on the current metrics, the company appears fairly valued. Key ratios include a P/E ratio of 60, an EV to EBITDA of 42.53, and a PEG ratio of 11.32, which suggest that while the company is priced at a premium, it may be justified given its strong performance metrics. In comparison to its peers, IDEXX Laboratories has a higher P/E ratio than Abbott Laboratories at 18.36 and Thermo Fisher Scientific at 30.06, but is lower than Intuitive Surgical at 63.32, indicating a competitive valuation landscape. Notably, IDEXX's ROE stands at an impressive 61.71%, showcasing its efficient use of equity. Over the past year, IDEXX has returned 38.13%, significantly outperforming the S&P 500's 14.08%, reinforcing the notion that the stock is positioned we...

IDEXX Laboratories, Inc. Experiences Evaluation Adjustment Amidst Mixed Market Indicators

2025-10-07 19:51:23

IDEXX Laboratories, Inc. has recently adjusted its market evaluation, with its stock priced at $627.78. The company has shown strong performance over the past year, achieving a 31.43% return, significantly outperforming the S&P 500. Technical indicators present a mixed outlook, reflecting varying trends across different time frames.

Is IDEXX Laboratories, Inc. technically bullish or bearish?

2025-10-07 12:13:59

As of 3 October 2025, the technical trend for IDEXX Laboratories, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the monthly MACD and KST indicators, which are both bullish, while the daily moving averages also indicate a mildly bullish trend. However, the weekly MACD and RSI are bearish, suggesting some short-term weakness. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, supporting the overall mildly bullish outlook. In terms of multi-period returns, IDEXX has outperformed the S&P 500 year-to-date and over the past year, with returns of 51.84% and 31.43% respectively, compared to the S&P 500's 14.18% and 17.82%. However, over longer periods, such as 3 years and 5 years, IDEXX has lagged behind the S&P 500....

Is IDEXX Laboratories, Inc. technically bullish or bearish?

2025-10-06 12:04:18

As of 3 October 2025, the technical trend for IDEXX Laboratories, Inc. has changed from bullish to mildly bullish. The weekly MACD and KST indicators are bullish, while the weekly RSI is bearish, indicating mixed signals. The daily moving averages are mildly bullish, and Bollinger Bands show a mildly bullish stance on both weekly and monthly time frames. However, Dow Theory presents a mildly bearish view on the weekly chart but is mildly bullish on the monthly. In terms of performance, IDEXX has outperformed the S&P 500 year-to-date with a return of 52.67% compared to the S&P 500's 14.18%, and over the past year, it has also outperformed with a return of 30.54% versus 17.82%. Overall, the current technical stance is mildly bullish, driven by the bullish MACD and KST, despite some bearish signals from the RSI and Dow Theory....

View All News